Abstract: A mounting bracket is configured to accommodate a memory card or a hard disk. The mounting bracket includes a base plate, two side plates, a plurality of protruding bumps and at least two supporting structures. The side plates are respectively connected to two opposite edges of the base plate, and extend along a direction perpendicular to the base plate. The protruding bumps are disposed on the base plate and protrude towards the direction. The supporting structures are located between the side plates and respectively disposed on the side plates. When the mounting bracket accommodates the memory card, the protruding bumps are configured to support the memory card. When the mounting bracket accommodates the hard disk, the supporting structures are configured to support the hard disk.

Abstract: A charging load detection circuit includes a charging circuit, a frequency generation unit, and a control unit. The control unit controls the frequency generation unit to generate a pulse voltage with a fixed first frequency and a fixed first amplitude, and the frequency generation unit provides the pulse voltage to an output terminal of the charging circuit. The control unit detects whether a load is coupled to the output terminal by detecting whether the first frequency and the first amplitude are varied, and controls connecting or disconnecting a charging path of the charging circuit according to whether the load is coupled to the output terminal.

Abstract: The disclosure provides an adjustable fixing assembly. The adjustable fixing assembly includes a base plate and a cover plate. The cover plate includes a plate portion and a protrusion portion protruding from the plate portion. The cover plate includes a first installation position and a second installation position. When the cover plate is in the first installation position, the protrusion portion extends away from the base plate, and the cover plate is spaced apart from the base plate by a first minimum distance. When the cover plate is in the second installation position, the protrusion portion extends towards the base plate, and the cover plate is spaced apart from the base plate by a second minimum distance, where the second minimum distance is smaller than the first minimum distance.

Abstract: The present invention provides a crystal form of a renal outer medullary potassium channel inhibitor and a preparation method thereof. In particular, the present invention provides crystal form III of a L-tartrate of a renal outer medullary potassium channel (ROMK) inhibitor (I) and a preparation method thereof. The crystal form III has good chemical stability and crystal form stability, and the crystallization solvent used has low toxicity and residue. Thus, the present invention can be better used in clinical treatment.

Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.

Abstract: The present invention provides a method for preparing a pharmaceutical composition containing a quinoline derivative or a salt thereof. Specifically, the invention provides a method for preparing a pharmaceutical composition containing (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)-propeneamide or a pharmaceutically acceptable salt thereof. The method uses a wetting agent containing at least one organic solvent for a wet granulation in a preparation process of the pharmaceutical composition. The pharmaceutical composition prepared using the method has a uniform distribution of grain sizes during the preparation process and a property of rapid and uniform dissolution.

Abstract: The present invention provides a pharmaceutical composition containing a quinoline derivative or a salt thereof. Specifically, the invention provides a pharmaceutical composition containing (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)-propeneamide or a pharmaceutically acceptable salt thereof, a cross-linked polyvinylpyrrolidone, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition has a property of rapid dissolution.

Abstract: A pharmaceutically acceptable salt as a renal outer medullary potassium channel (ROMK) inhibitor, specifically an L-tartrate and a crystal form I and crystal form II thereof, is described. The pharmaceutically acceptable salt of the ROMK inhibitor, specifically the L-tartrate, has improved bioavailability and stability.

Abstract: The present invention relates to a crystalline form of a BTK kinase inhibitor and the preparation method thereof. In particular, the present invention relates to a crystal form I of (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6 -difluorophenoxy)phenyl)-1 H-pyrrolo[2,3-d]pyridazin-7(6H)-one (the compound of formula (I)) and the preparation method thereof. The crystal form I of the compound of formula (I) obtained by the present invention has a good crystalline stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, thus making it more suitable for use in clinical treatment.

Abstract: Electrically conductive polymeric composite materials include microbially produced protein nanowires. The conductive composites are useful in diverse electronic materials applications, particularly in applications requiring biocompatibility, such as sensors and wearable electronics.

Abstract: Provided in the present invention is a pharmaceutical composition containing an imidazoline derivative. In particular, the pharmaceutical composition provided in the present invention contains (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile and cellulose ether; and the composition has a good stability, dissolution rate and bioavailability.

Abstract: Provided are an L-proline complex of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline complex. Specifically, provided are 1,6-dehydrated-1-C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl}-5-C-(hydroxymethyl)-?-L-idopyranose L-proline (a compound of formula (I)), a monohydrate and a type A crystal thereof, and a preparation method therefor. The obtained type A crystal of the compound of formula (I) has good chemical stability and crystal stability, and the crystallization solvent used has low toxicity and low residue, so the type A crystal can be better used in clinical treatment.

Abstract: Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.

Abstract: Disclosed is a pregabalin sustained-release preparation, wherein the sustained-release tablet contains a pharmaceutically active ingredient containing pregabalin or a salt or hydrate thereof, a gel framework material containing alginic acid, and a swellable material containing polyoxyethylene.

Abstract: The present invention relates to a formulation of ticagrelor or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to an improved formulation of ticagrelor or a pharmaceutically acceptable salt thereof, which is administered once a day. In the present invention, the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL within 2 hours; and the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL at 12 hours after administration; and the maximum plasma concentration (Cmax) of ticagrelor or a pharmaceutically acceptable salt thereof in a subject is between about 0.2 ?g/mL and about 0.8 ?g/mL. The formulation of the present invention can reduce the frequency of administration, thereby improving patient compliance and reducing the risk of myocardial infarction or stroke induced by acute thrombosis which is caused by missed administration of ticagrelor.

Abstract: The present invention provides a method for preparing a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt thereof. Specifically, the invention provides a preparation method of a pharmaceutical composition, the method containing: mixing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof with at least one filler, and then granulating the mixture. The pharmaceutical composition of the invention features a rapid dissolution and good stability.

Abstract: The present invention provides a method for preparing a pharmaceutical composition containing a quinoline derivative or a salt thereof. Specifically, the invention provides a method for preparing a pharmaceutical composition containing (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)-propeneamide or a pharmaceutically acceptable salt thereof. The method uses a wetting agent containing at least one organic solvent for a wet granulation in a preparation process of the pharmaceutical composition. The pharmaceutical composition prepared using the method has a uniform distribution of grain sizes during the preparation process and a property of rapid and uniform dissolution.

Abstract: The present invention provides a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt of the compound. Specifically, the invention provides a pharmaceutical composition containing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof, and at least one water soluble filler. The pharmaceutical composition of the invention features a rapid dissolution and good stability.

Abstract: Provided in the present invention is a pharmaceutical composition containing an imidazoline derivative. In particular, the pharmaceutical composition provided in the present invention contains (S)-4-(3-(4-(2,3-dihydroxypropoxy) phenyl)-4,4-dimethyl-5-carbonyl-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl) benzonitrile and cellulose ether; and the composition has a good stability, dissolution rate and bioavailability.

Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR,5s, 6aS)—N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.